Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Gyre — Income Tax Expense Benefit

Other segment segments

Gyre Pharmaceuticals
-$165K-125%

Similar metrics at other companies

Principal Financial Group logo
PFGSegment Benefits And Protection — Income Tax Expense Benefit
$25.3M+13.7%
Advance Auto Parts logo
AAPReportable — Income Tax Expense Benefit
$11M+107%
Ollie's Bargain Outlet Holdings, Inc. logo
OLLIOllies — Income Tax Expense Benefit
$18.12M+35.1%
BioSig Technologies, Inc. logo
STEXCorporate — Income Tax Expense Benefit
$565K
CPH
CPHCDevelopment — Income Tax Expense Benefit
-$473K+8.2%
NXT
NXTTCODM — Income Tax Expense Benefit
-$13.23M-142%

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$712.55M+11.2%
Enterprise value$672.68M+11.0%
P/S-0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0.0×
Current ratio4.3×-1.1×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-340448
Line itemThree Months Ended June 30,Six Months Ended June 30,
Other expense, net(488))(301))
Change in fair value of warrant liability2122,467
(Loss) Income before income taxes(1,575))4,265)
Benefit (provision) for income taxes(662)(1,563))
Net (loss) income(2,237))2,702)
Accretion of Cullgen redeemable convertible preferred stock(2,642))(5,220))
Net loss attributable to noncontrolling interest(2,835))(2,644))
Net (loss) income attributable to common stockholders$$(2,044))$$126)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Gyre Therapeutics, Inc.'s gyre — income tax expense benefit?
Gyre Therapeutics, Inc. (GYRE) reported gyre — income tax expense benefit of $1K in Q2 2026.
What is the long-term trend for Gyre Therapeutics, Inc.'s gyre — income tax expense benefit?
Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre — income tax expense benefit has grown at a -42.3% compound annual growth rate (CAGR), from $6K to $2K.
What does gyre — income tax expense benefit mean?
This metric represents the total income tax expense or benefit recognized by the specific business segment during the reporting period. It reflects the tax impact of the segment's operations, including current and deferred tax provisions. Monitoring this helps investors understand the tax efficiency and regulatory impact on the segment's bottom line.

Ask your AI about Gyre Therapeutics, Inc.'s gyre — income tax expense benefit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude